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The post-translational modiﬁcation of histone proteins plays an important role in controlling cell
fate by directing essentially all DNA-associated nuclear processes. Misregulation and mutation of
histone modifying enzymes is a hallmark of tumorigenesis. However, how these different epigenetic
modiﬁcations lead to tumor initiation and/or progression remains poorly understood. Recent stud-
ies have uncovered a potential tumor suppressor role for histone H2B monoubiquitination
(H2Bub1). Like many other histone modiﬁcations, H2Bub1 has diverse functions and plays roles
both in transcriptional activation and repression as well as in controlling mRNA processing and
directing DNA repair processes. Notably, H2Bub1 has been linked to transcriptional elongation
and is preferentially found in the transcribed region of active genes. Its activity is intimately
connected to active transcription and the transcriptional elongation regulatory protein cyclin-
dependent kinase-9 (CDK9) and the facilitates chromatin transcription (FACT) complex. This review
provides an overview of the current understanding of H2Bub1 function in mammalian systems with
a particular emphasis on its role in cancer and potential options for exploiting this knowledge for
the treatment of cancer.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Histone modiﬁcations
Epigenetic modiﬁcations are essential in controlling DNA asso-
ciated processes such as cell type-speciﬁc gene expression, DNA
replication and DNA repair. While much focus has been placed
on DNA methylation, post-translational modiﬁcations of core his-
tones also play an essential, but only poorly understood role in
these processes. Chromatin is the composite of packaged nuclear
DNA with its associated proteins. The basic unit of chromatin is
the nucleosome containing approximately 147 bp of DNA wrapped
around an octamer containing two each of histones H2A, H2B, H3
and H4. Histone octamers are then packaged into higher order
chromatin structures by the interactions between individual
nucleosomes and the binding of other proteins such as the linker
histone H1, heterochromatin protein 1 (HP1), etc. Each of the core
histones can be modiﬁed by a number of post-translational modi-
ﬁcations such as the methylation of arginine and lysine residues,
acetylation of lysine residues and phosphorylation of serine or
threonine residues. Modiﬁcations of the core histones have been
hypothesized to make up a ‘‘histone code’’ which controls DNA-
associated processes in different ways according to the repertoire
of modiﬁcations present at a given chromatin region [1,2]. Further-
more, a number of other post-translational modiﬁcations of his-
tones such as formylation [3,4], sumoylation [5], crotonylational Societies. Published by Elsevier[6], ADP-ribosylation [7], etc., have been identiﬁed, but their func-
tions remain mostly enigmatic.
In addition to the more common modiﬁcations like methyla-
tion, acetylation and phosphorylation, histones H2A and H2B can
also be monoubiquitinated [8]. In comparison to the aforemen-
tioned modiﬁcations, monoubiquitination is unique in that it is
much larger (8.5 kDa) and thereby has important steric conse-
quences for chromatin structure. Monoubiquitination of histone
H2A (H2Aub1) is carried out by the Polycomb Repressor Complex
1 (PRC1) and is associated with the repression of developmental
genes such as the Hox gene cluster [8]. In contrast to the apparent
repressive function of H2Aub1, the monoubiquitination of histone
H2B (H2Bub1) is associated with gene activation [9–11]. Interest-
ingly, while H2Aub1 serves to repress Hox genes, H2Bub1 is re-
quired for active Hox gene transcription [11]. Furthermore,
H2Bub1 and H2Aub1 not only play roles in transcription, but also
have functions in other DNA-associated processes such as DNA
repair [12–17] as well as mRNA processing [18–20] and transport
[21].
Much of what is known about H2Bub1 has come from studies in
yeast. However, a number of factors complicate a simple transfer of
this understanding to the mammalian system and applying it for
understanding complex cellular programs such as differentiation
and tumorigenesis. This review summarizes the current state of
the literature concerning the functional role and involvement of
histone H2B monoubiquitination and its modifying enzymesB.V. Open access under CC BY-NC-ND license. 
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cellular processes.
2. H2Bub1 and transcription
Gene-speciﬁc as well as genome-wide studies have revealed
that H2Bub1 is associated speciﬁcally with the transcribed
region of active genes in mammals [9,22]. Furthermore, similar
to other marks of active genes, such as H3K36me3, the amount
of H2Bub1 present in the transcribed region of genes generally
correlates with the transcription rates of the given gene. Given
its correlation with gene transcription rates and its proposed
role in transcriptional elongation, it is frequently assumed that
H2Bub1 is universally required for gene transcription. However,
in fact, knockdown of either RNF20 or RNF40 selectively affects
a very moderate number of genes [22,23]. Additionally, while
H2Bub1 may be required for the expression of some genes
[11,23] it also appears to suppress the transcription of others
[22].
The positive role of H2Bub1 in both transcriptional elongation
as well as DNA repair is likely through cooperation with the FACT
histone chaperone complex [10,23]. The transcriptional suppres-
sion effects observed on other genes may be linked to decreased
recruitment of the transcriptional elongation factor TFIIS to certain
protooncogenes [24]. Thus, the tumor suppressor role of H2Bub1
and its ubiquitin ligases RNF20 and RNF40 likely consists of a com-
bination of positive and negative gene expression effects as well as
to their roles in DNA repair (see below).
3. The CDK9-WAC-RNF20/40 axis
Earlier studies in both yeast [25–28] and mammals [10,11],
as well as its association with the transcribed region of active
genes in mammals [9], suggested that H2Bub1 plays a role in
transcriptional elongation. One of the central factors that regu-
late transcriptional elongation in metazoans is the positive tran-
scription elongation factor-b (P-TEFb) complex which contains
the cyclin-dependent kinase-9 (CDK9) and its associated cyclin
T subunit [29]. CDK9 functions to coordinate transcriptional
elongation and cotranscriptional processes by phosphorylating
Ser2 of the Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7 heptapeptide
repeat of the carboxy-terminal domain (CTD) of RNA Polymerase
II (RNAPII; Fig. 1). The CDK9 orthologues Bur1 and/or Ctk1 carry
out this function in yeast [30]. Given the similar pattern of
localization of H2Bub1 [9] and RNAPII CTD Ser2 phosphorylation
[31] on the active p21 gene we hypothesized that there might
be a direct connection between the two. Indeed, inhibition of
CDK9 activity, depletion of CDK9 or a S2A mutation of the RNA-
PII CTD resulted in a loss of global and gene-associated H2Bub1
while CDK9 overexpression increased H2Bub1 [20]. A direct
interaction between the Ser2 phosphorylation of the RNAPII
CTD and H2Bub1 was later shown to occur through the WW-
domain containing adaptor with coiled coil protein (WAC),
which is part of the RNF20/RNF40 complex [32]. Like CDK9,
WAC expression is required for global and gene-associated lev-
els of H2Bub1.
Interestingly, while Bur1 is also required for maintaining
H2Bub1 in yeast [27,33], this effect is likely independent of Ser2
phosphorylation [28]. Furthermore, while the PAF complex
appears to be essential for recruitment of the Bre1/Rad6 complex
to chromatin in yeast [33] through direct interations [34], and a
requirement for PAF in maintaining H2Bub1 in mammals has been
reported [11], other data suggest that PAF may control H2Bub1
indirectly in mammals through regulation of the transcriptional
machinery [32].4. H2Bub1 and nuclear hormone receptor activity
Surprisingly, while H2Bub1 is universally present on most ac-
tive genes, the vast majority of transcription in the cell appears
to be relatively insensitive to the presence or absence of H2Bub1.
This suggests that the H2Bub1-regulated genes have speciﬁc prop-
erties. Interestingly, transcriptional activation by some, but not all,
nuclear hormone receptors appears to particularly rely on dynamic
ubiquitination and deubiquitination of H2B. For example, both the
estrogen receptor [23] and the androgen receptor [35] require
RNF20 and RNF40 for the optimal expression of target genes. Sur-
prisingly, while RNF40 knockdown permits estrogen-independent
growth of breast cancer cells [23], depletion of either RNF20 or
RNF40 in prostate cancer cells decreases androgen-stimulated pro-
liferation [35].
Consistent with data from yeast indicating that both the dy-
namic ubiquitination and deubiquitination of H2B are essential
for repeated cycles of transcription, the H2B ubiquitin speciﬁc pro-
tease-22 (USP22) is also required for both androgen receptor and
estrogen receptor-dependent transcription [36]. To complicate
things even more, both the RNF20/40 and USP22 complexes appear
to associate directly with the androgen receptor [35,36].
How do we rectify the H2B ubiquitination/deubiquitination di-
lemma? A previous study demonstrated cycling of both activators
and repressors during transcriptional activation [37]. Similarly,
while H2Bub1 is likely required for dynamic modulation of chro-
matin structure, subsequent deubiquitination may be essential
for ‘‘resetting’’ the activated gene to a status that allows subse-
quent rounds of transcription. While this may be true in some
cases, other genes appear to be regulated in a different manner.
For example, induction of the interferon-regulated gene IRF1 is de-
creased following USP22 knockdown [18] while knockdown of
RNF20 increases IRF1 induction [38]. Thus, for the IRF1 gene, these
two enzymes play opposing roles during the induction of tran-
scription. However, how and when RNF20/40 or USP22 interact
with the same transcription factors and how this is regulated in
a temporal and context-dependent manner remains unknown
and will need to be addressed by performing kinetic chromatin
immunoprecipitation experiments against the various factors as
well as H2Bub1 on a genome-wide level to determine when and
where they are recruited to various target genes following hor-
mone treatment.
5. Nucleosome stabilizer or chromatin opener?
The question still remains, what does H2Bub1 actually do? Most
likely H2Bub1 serves to facilitate dynamic changes in chromatin
structure. Consistent with this hypothesis, rapidly induced genes,
which likely require rapid and signiﬁcant changes in chromatin
structure, appear to be particularly sensitive to depletion of
H2Bub1 [10,18,22–24,38]. This rapid induction of gene expression
may be due in part to the cooperation between H2Bub1 and the
FACT complex which promotes nucleosome disassembly and reas-
sembly in both yeast [25] and mammals [10,39]. However, how
H2Bub1 and FACT cooperate and whether there is a direct physical
interaction between them remains unclear. One possibility is that
the structure of H2Bub1-containing nucleosomes provides a topol-
ogy that makes the nucleosome and DNA more accessible to his-
tone chaperones and other chromatin modifying enzymes. The
development of new technology enabling the generation of recom-
binant H2Bub1 [40] allowed for additional in vitro analyses of
H2Bub1 function. Notably, H2Bub1 disrupts higher order chroma-
tin structure in vitro [41] and increased micrococcal nuclease
(MNase) sensitivity in vivo [41,42]. This effect appears to be due
to the placement of the ubiquitinated lysine residue (K120 in
Fig. 1. The CDK9-WAC-RNF20/40-H2Bub1 regulatory axis. During gene transcription, cyclin-dependent kinase-9 (CDK9) phosphorylates Ser2 on the YSPTSPS heptapeptide
repeat sequence within the RNA Polymerase II (RNA Pol II) carboxy-terminal domain. This phosphorylation serves as a binding platform for the WW-domain containing
adaptor with coiled coil protein (WAC) which further recruits the RNF20/RNF40 heterodimer to the elongating RNA Pol II. Simultaneously, CDK9 phosphorylates the ubiquitin
conjugating enzyme UBE2A on Ser120, thereby increasing its activity. Together, this complex monoubiquitinates histone H2B at lysine 120 near its carboxyl terminus.
Monoubiquitinated H2B (H2Bub1) serves to increase the ability of the histone chaperone complex Facilitates Chromatin Transcription (FACT) to catalyze the exchange of an
H2A:H2B dimer, thereby increasing RNA Pol II processivity. This process is antagonized by the deubiquitinating module of the SAGA complex containing ubiquitin-speciﬁc
protease-22 (USP22), Ataxin 7 (ATXN7), Ataxin 7-like 3 (ATXN7L3) and Enhancer of Yellow Homologue-2 (ENY2).
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30 nm model of chromatin structure [41]. The placement of the
8.5 kDa ubiquitin moiety at this interface presumably interferes
with stacking of adjacent nucleosomes in the 3-dimensional struc-
ture of chromatin. Surprisingly, this effect appears to be more com-
plex than just a steric hindrance effect, since the addition of
another bulky modiﬁcation (HUB1) did not elicit such effects [41].
Although H2Bub1 likely functions to open chromatin structure,
this effect appears to be more complicated than that. In contrast
with its universal association with active gene transcription, the
presence or absence of H2Bub1 on a gene may serve to facilitate
or repress gene transcription in a context-dependent manner that
is not completely understood [22,24]. One mechanism by which
H2Bub1 may serve to suppress gene transcription likely involves
occlusion of the transcriptional elongation factor TFSII from chro-
matin [24], although how H2Bub1 interacts with this factor re-
mains unclear. Counter intuitive to a role of H2Bub1 in
promoting transcription and nucleosome dynamics, studies in
yeast revealed that H2Bub1-containing nucleosomes are actually
more stable [43–45]. Interestingly, these effects of H2B monoubiq-
uitination also appear to be speciﬁc for ubiquitin since the conju-
gation of a similar bulky modiﬁcation (sumoylation) to H2B did
not lead to increased nucleosomal stability [44].
How can the apparent contradictory roles of H2Bub1 in opening
chromatin structure and promoting nucleosome stability be ex-
plained? One explanation is that the effects and role of H2Bub1
may be different in yeast and mammals. Notably, while H2Bub1
is prominently present near the transcriptional start site of genesin yeast as well as in the transcribed region [25,43,46,47], it is pref-
erentially localized in the transcribed region of active genes in hu-
mans, with signiﬁcantly lower levels near the transcriptional start
site [9,20,22,32,38,48]. Notably, the ability of H2Bub1 to activate or
repress transcription may be dependent upon its localization on
the target gene. Recent genome-wide groundbreaking studies in
yeast demonstrated that genes which required H2Bub1 for active
transcription generally showed higher H2Bub1 enrichment in the
transcribed genes, while H2Bub1-repressed genes showed a great-
er enrichment in the promoter region [43]. Whether this model
also holds true in mammalians must be systematically analyzed.
However, initial genome-wide studies in human cells did not un-
cover increased enrichment of H2Bub1 in the promoter region of
H2Bub1-repressed genes [22].
Furthermore, it is not clear how additional histone modiﬁca-
tions such as H3K36me3, which show a similar enrichment in
the transcribed regions of active genes, may inﬂuence nucleosome
stability and MNase sensitivity. Additional in vitro studies on the
physical properties of H2Bub1-containing nucleosomes as well as
genome-wide studies of H2Bub1 occupancy coupled with the anal-
ysis of gene expression may reveal new insights into the function
of this histone modiﬁcation during gene transcription. Further-
more, given the rapid nature of ubiquitination and deubiquitina-
tion of H2B, the presence alone of H2Bub1 on the chromatin (i.e.,
observed during ChIP analyses) may not necessarily be indicative
of where it is primarily functioning. Genome-wide studies similar
to the individual gene studies by Chipumoro and Henriksen [18]
comparing the localization of H2Bub1 with H2B deubiquitinating
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will be important for determining how dynamic changes in
H2Bub1 control gene expression. Furthermore, additional studies
to determine the contribution of these enzymes to mRNA process-
ing and transport will be essential for understanding their biolog-
ical functions.
6. H2B DUBs
As stated above, H2Bub1 is highly dynamic and is regulated by
rapid ubiquitination and deubiquitination. In yeast, H2B is deubiq-
uitinated by the ubiquitin speciﬁc proteases Ubp8 [46,49] and
Ubp10 [50,51]. Recent data demonstrate that Ubp8 and Ubp10
deubiquitinate different pools of H2Bub1, dependent upon the
chromatin context [52]. Like its human orthologue USP22
[36,53], Ubp8 is part of the deubiquitinating module of the SAGA
transcriptional regulatory complex [46,49]. Both Ubp8 and USP22
contain a unique amino-terminal zinc ﬁnger domain which is re-
quired for its DUB activity.
A role for USP22 in tumorigenesis was suggested by its discov-
ery as part of an 11 gene ‘‘stem cell signature’’ which accurately
predicts patient outcome [54]. Subsequent studies support that
USP22 is overexpressed in colon [55,56] and breast cancer [57]
and correlates with poor prognosis. Similarly, USP22 knockdown
decreases cell proliferation in several cancer cell lines [53,58,59].
However, while USP22 is capable of deubiquitinating H2B
in vitro [36,53,60] and USP22 knockdown increases H2Bub1 levels
on the IRF1 gene [18], none of the published reports demonstrated
a signiﬁcant change in global H2Bub1 levels following USP22
knockdown. This is particularly surprising since knockdown of
the SAGA DUB module component ATXN7L3 signiﬁcantly increases
global and gene associated H2Bub1 levels [60]. In fact, it is likely
that additional DUBs play a role in controlling H2Bub1 levels in a
temporal and context-dependent manner. In particular, a tblastn
search revealed that both USP27X (31% over 478 amino acids)
and USP51 (30% over 474 amino acids) demonstrate a degree of
homology to Ubp8 similar to that of USP22 (32% identity over
462 amino acids). Furthermore, USP27X was previously identiﬁed
as an interaction partner of USP22 [61]. Thus it is quite likely that
USP22, USP27X, USP51 and perhaps other DUBs have overlapping
functions in certain tissues. Additional studies will be necessary
to determine whether these DUBs are also part of the SAGA com-
plex and what their contribution to H2B deubiquitination may be.
In addition to USP22, several other proteins including USP3
[62], USP7 [63], USP12 [64], and USP46 [64] have been identiﬁed
as H2B DUBs in humans. Furthermore, analysis of the mass spec-
trometry data from Sowa et al., identiﬁes histones as interaction
partners with the highest Z-scores for USP8 and USP44 [61]. How-
ever, the signiﬁcance of any of these DUBs in controlling H2Bub1
and H2Bub1-dependent processes remains open.
7. Two ubiquitin ligases for one modiﬁcation?
While Saccharomyces cerevisiae, Drosophila and Caenorhabditis
elegans only appear to have one homologue of the yeast H2B ubiq-
uitin ligase Bre1, the ﬁssion yeast Schizosaccharomyces pombe and
most metazoans have two separate genes each encoding closely re-
lated orthologues of the Bre1. Interestingly, while Bre1 appears to
form a homodimer in budding yeast, an apparent obligate hetero-
dimer is required in most metazoans. For example, although some
reports suggested only RNF20 is important for H2B monoubiquiti-
nation, a number of studies establish that both RNF20 and RNF40
are required for maintaining H2Bub1 levels in human cells
[20,23,39,65,66]. Furthermore, the stability of each partner is
dependent upon the presence of the other such that depletion ofeither component results in a substantial decrease in the other as
well. Surprisingly, in a series of in vitro studies, Kim et al., demon-
strated that while the presence of both RNF20 and RNF40 is re-
quired for H2Bub1 in vitro and in vivo, only the RING ﬁnger of
RNF20 was essential for in vitro monoubiquitination of H2B [48].
Although additional cell-based studies will be essential to
determine whether RNF40 ubiquitin ligase activity is indeed dis-
pensable for H2B monoubiquitination in vivo, this brings up an
interesting question. If the RING ﬁnger domain (and thus, the ubiq-
uitin ligase activity) of RNF40 is not essential for maintaining
H2Bub1 levels, what is its purpose? Why would an intact RING ﬁn-
ger domain be maintained throughout metazoan evolution? Most
likely there is more to the biology of RNF20 and RNF40 than just
H2B monoubiquitination. In support of this, additional substrates
of both RNF20 [67] and RNF40 [68] have been reported. However,
the signiﬁcance of these substrates is unclear. It is also unclear
whether RNF20 and RNF40 function as a heterodimer in ubiquiti-
nating these proteins. Additional interaction and mass spectrome-
try studies will help to uncover additional substrates of RNF20 and
RNF40 and determine their importance in eliciting the biological
effects of these very interesting ubiquitin ligases.
8. Other H2B ubiquitin ligases?
In S. cerevisiae Bre1 appears to be the sole H2B ubiquitin ligase
[69]. However, in addition to RNF20 and RNF40, other ubiquitin li-
gases such as RNF8 [70], MDM2 [71] and a BAF250/ARID1 complex
containing elongin C [72] have been reported to function as H2B
ubiquitin ligases. However, the role of RNF8 in controlling
H2Bub1 has been challenged by a recent report [66] and the ability
of MDM2 to ubiquitinate H2B appears to be limited to free H2B,
rather than in a native nucleosomal context [11,71]. Furthermore,
although BAF250/ARID1 may be required for maintaining global
H2Bub1 levels in HEK293 cells, it is unclear whether this effect
in vivo is dependent upon its interaction with the ubiquitin ligase
elongin C [72]. An earlier study showed that ARID1 also interacts
with ENL [73], which is part of a larger complex that stimulates
transcriptional elongation by recruiting CDK9 [74,75]. Given the
connection between CDK9 and H2Bub1, additional studies will be
necessary to decipher the contribution of the interactions between
BAF250/ARID1 and ENL versus elongin C in regulating H2B
monoubiquitination.
9. DNA repair and genomic stability
In addition to its role in transcription, a substantial amount of
evidence has accumulated that RNF20, RNF40 and H2Bub1 play an
important role in controlling DNA repair and cell cycle checkpoint
activation [76]. Both RNF20 [77,78] and RNF40 [78,79] were identi-
ﬁed as substrates of the ATM and ATR kinases in mass spectrometry
studies. The phosphorylation of both RNF20 and RNF40 by ATM,
albeit at different positions than those previously described, were
further substantiated in a recent study [66]. Although the study
by Mu et al., suggested that RNF20 or RNF40 knockdown affected
cell cycle checkpoint activation [78], a deﬁnitive and mechanistic
role for RNF20 and RNF40 in DNA double-strand break (DSB) repair
remained unknown until recently. Chernikova et al. ﬁrst showed
that RNF20 and RNF40 knockdown increased radiosensitivity and
their expressionwas essential for proper recruitment of proteins in-
volved in homologous recombination repair [80]. This study was
further supported by studies which provided substantial additional
mechanistic insights into RNF20 and RNF40 function in homologous
recombination and non-homologous end joining DNA repair and a
deﬁnitive role for H2Bub1 in this process [66,81]. Importantly, these
studies demonstrated that RNF20 and RNF40 are recruited to the
Table 1
In vivo evidence for misregulation of the H2B monoubiquitination pathway in cancer.
Protein Function in relation to H2Bub1 Evidence for a Role in Cancer Ref.
BRD4 Recruits CDK9 to chromatin Mutated in ovarian cancer [105]
Changes in activity affect metastatic properties in breast cancer [102–104]
Inhibition decreases hematological malignancy [99–101]
CCNT1 Cyclin subunit for CDK9 Mutated in ovarian cancer [105]
CDC73 Polymerase-associated factor (PAF) complex
component essential for H2B monoubiquitination
Frequently mutated in parathyroid cancer [106–119]
H2Bub1 – Decreased during breast cancer progression [23]
RNF20 H2B ubiquitin ligase (K120) Mutated in colon cancer, head and neck squamous cell carcinoma,
melanoma, ovarian cancer
[105,120–122]
Decreased protein levels in testicular cancer [65]
Promoter is methylated in breast cancer [22]
Increased tumor burden following RNF20 knockdown in Xenografts [22]
RNF40 H2B ubiquitin ligase (K120) Locus on 16p is ampliﬁed in invasive lobular breast carcinoma [123]
Mutated in glioblastoma multiforme [124]
USP22 Removal of H2Bub1 Associated with stem cell phenotype and poor prognosis [54]
Elevated protein levels in breast and colorectal cancer [55,57]
Table 2
In vitro evidence for a tumor suppressor role for the H2B monoubiquitination pathway.
Protein Function in relation to H2Bub1 Evidence for a role in cancer Ref.
H2Bub1 – Required for proper DNA repair [66,81]
RNF20 H2B ubiquitin ligase Knockdown increases cell migration [22]
Required for proper DNA repair [66,80,81]
Implicated in genomic stability [65]
Coactivates p53-mediated transcriptional activation [32,125]
Controls androgen receptor activity [35]
RNF40 H2B ubiquitin ligase Suppresses cell migration [23]
Required for proper DNA repair [39,80]
Maintains genomic stability [65]
Transcriptional coactivator for p53 [32]
Controls estrogen receptor activity [23]
USP22 H2B deubiquitinating enzyme Knockdown decreases cell proliferation [53,58,59]
Required for nuclear hormone receptor-regulated gene transcription [36]
WAC Recruits RNF20/40 to phosphorylated RNA Pol II Coactivates p53-mediated gene transcription [32]
Required for cell cycle checkpoint activation after DNA damage [32]
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NBS1 [81].
In addition to an essential role in DNA double-strand break re-
pair, RNF20 and RNF40 (presumably through H2Bub1) appear to
play a role in suppressing replication stress and chromosomal
instability [65]. This effect appears to be due to the suppression
of DNA:RNA hybrid formation (R loops). R loops form as a result
of extended stable DNA:RNA hybrids during transcription. Deple-
tion of the mRNA splicing factors SC35 [82] or SF2/ASF [83] leads
to increased R loop formation and genomic instability by impairing
replication fork progression [84]. These effects can be reversed by
overexpression of RNase H1 [83] or the RNA binding protein RNPS1
[85]. Similarly, replication stress-induced DNA damage following
RNF40 knockdown was reversed by RNase H1 overexpression [65].
The effects of RNF40 knockdown on replication stress are rem-
iniscent of those observed following CDK9 knockdown in another
study [86]. In this case, CDK9 knockdown alone was sufﬁcient to
induce replication stress-induced DNA damage. Given the estab-
lished role of CDK9 and H2Bub1 in transcriptional elongation, to-
gether with the observation that SC35 promotes transcriptional
elongation by increasing CDK9 recruitment and P-Ser2 phosphory-
lation of RNAPII [87], it is quite likely that the transcription-cou-
pled functions of SF2/ASF, SC35, CDK9, H2Bub1, RNF20 and
RNF40 are likely related to their functions in suppressing Rloop-induced genomic instability. However, additional studies will
be necessary to speciﬁcally address the relationships between
these different factors in responding to replication stress and
how they function together.
10. H2Bub1 and its regulators in human tumors
A tumor suppressor role for H2Bub1 is supported by studies on
the RNF20 gene. One study demonstrated increased methylation of
the RNF20 promoter in breast cancer [22] while a more recent study
showed that RNF20 protein levels are decreased in seminoma [65].
Despite the potential implications of these results for H2Bub1 levels
in tumors, only one study to date has directly investigated the levels
of H2Bub1 in primary tumor samples [23]. Consistentwith a role for
H2Bub1in cancer, this study demonstrated that while H2Bub1 was
easily detected in normal mammary epithelium and in benign
mammary tumors, the overwhelming majority of malignant and
metastatic breast cancers displayed undetectable levels of
H2Bub1 [23]. Thus, in breast cancer H2Bub1 appears to correlate
more with tumor progression and differentiation status than with
tumor initiation. Exactly how decreased H2Bub1 contributes to tu-
mor progression is unclear but likely involves a combination of
changes in protooncogene expression [22], increased cell survival
signaling and estrogen-independent growth [23], increased cell
Fig. 2. Potential therapeutic targets in the H2Bub1 regulatory pathway. The balance
of histone acetylation and deacetylation can be controlled by the use of histone
deacetylase (HDAC) inhibitors. Increased histone acetylation can thereby increase
BRD4 recruitment to chromatin. Novel bromodomain and extraterminal (BET)
domain inhibitors which speciﬁcally bind the chromatin-binding domain of
bromodomain protein-4 (BRD4) block its recruitment to chromatin. After recruit-
ment to chromatin, BRD4 further recruits cyclin-dependent kinase-9 (CDK9) which
in turn phosphorylates ubiquitin-conjugating enzyme E2A (UBE2A) at Ser120 and
RNA Polymerase II (RNA Pol II) on Ser2 of its carboxy-terminal domain (CTD). These
phosphorylations help serve to activate UBE2A activity and facilitate binding of the
WAC/RNF20/RNF40 complex, respectively. This can be inhibited by speciﬁc CDK9
inhibitors. Finally, the RNF20/RNF40/WAC complex utilizes free ubiquitin to
monoubiquitinate histone H2B at lysine 120, thereby facilitating DNA repair or
altering gene expression to increase cellular differentiation. H2B monoubiquitina-
tion can be blocked through depletion of the free ubiquitin pool by proteasome
inhibitors.
S.A. Johnsen / FEBS Letters 586 (2012) 1592–1601 1597migration [22,23], decreased DNA double-strand break repair
[39,66,80,81] and increased chromosomal instability [65].
11. H2Bub1 as a therapeutic target
If changes in H2Bub1 indeed play an important role in cancer as
implied by numerous studies (Tables 1 and 2), this pathway may
potentially be exploited for the tumor therapy. There are a number
of possibilities that can be imagined to exploit the pathways posi-
tively and negatively regulating H2Bub1 (Fig. 2).
In order to exploit H2Bub1 as a potential therapeutic target, it
will probably ﬁrst be necessary to determine the H2Bub1 status
of patient tumors and put this into the context of other clinical
parameters including (i.e., HER2 and nuclear receptor status for
breast cancer). For example, restoring H2Bub1 levels may be
advantageous in primary breast carcinoma and metastasis. In this
case, treatments such as decitabine (5-aza-20deoxycytidine) might
be advantageous in restoring RNF20 expression in tumors where its
promoter is methylated. In tumors overexpressing USP22, speciﬁc
inhibitors such as those already developed for USP7 and USP8 are
imaginable [88]. In this respect, these treatments might decrease
cell proliferation by restoring a more differentiated cellular pheno-
type and responsiveness to anti-estrogen therapies.
On the other hand, earlier stage tumors displaying signiﬁcant
levels of H2Bub1 may beneﬁt from therapies such as proteasome
inhibitors or CDK9 inhibitors which signiﬁcantly decrease
H2Bub1 levels [9,19,20,23,89]. It would be predicted that these
therapies would increase the sensitivity of tumor cells to chemo-
and radiotherapy by blocking H2Bub1-dependent DNA repair pro-
cesses. Indeed, consistent with this possibility, although protea-
some inhibitors and the CDK9 inhibitor ﬂavopiridol have been
poor therapeutic agents on their own, they signiﬁcantly potentiate
the effectiveness of DNA damaging agents [90–96]. Additional
studies may help to determine how much of this effect is elicited
by changes in the levels of H2Bub1.
Finally, although most data indicate that H2Bub1 and its
ubiquitin ligases function as tumor suppressors, a few studies sug-
gest that their activity may actually promote tumorigenesis
[35,42,67]. This effect may be due to tumor stage-dependent ef-
fects. Speciﬁcally, H2Bub1 may potentially play a more signiﬁcant
role in suppressing metastatic and cancer stem cell phenotypes.
Consistent with this, RNF20 and 40 knockdown decrease cell pro-
liferation [35,42,65,67] but increase cell migration [22,23] and
in vivo tumor burden [22]. Moreover, H2Bub1 is clearly detectable
in early stage tumors, but absent in malignant and metastatic
breast cancers [23]. Consistently, the H2B deubiquitinating
enzyme USP22 correlates with poor patient outcome and a stem
cell gene expression signature [54].
Like H2Bub1, the role of CDK9 in cancer also appears to be com-
plicated and likely depends both upon tumor stage as well as the
type of malignancy. Importantly, CDK9 activity is essential for cell
proliferation in mixed lineage leukemia [75]. Consistently, new
chemical inhibitors of the bromodomain-containing protein
BRD4, which recruits CDK9 to chromatin [97,98], are effective in
combatting hematological malignancies [99–101]. In contrast,
BRD4 activity appears to suppress metastatic properties in breast
cancer without signiﬁcantly affecting cell proliferation [102–104].
Thus it will be important to determine the different roles of
H2Bub1 and its upstream regulatory pathway components includ-
ing CDK9, in different types of malignancies.12. Outlook
Although a signiﬁcant amount of interesting data has accumu-
lated suggesting a role for H2Bub1 and its upstream regulatorycomponents in cancer, a number of questions remain to be an-
swered. Some of the important remaining questions include:
What is the real role of H2Bub1 and its ubiquitin ligases in can-
cer? In order to answer this question, new conditional mouse
knockout models of Rnf20 and Rnf40 will be necessary to deter-
mine the effects of genetic ablation of these genes on tumor initi-
ation and progression in various tumor models. Additional studies
directly investigating the levels of H2Bub1 in different tumor types
and stages will also be important in determining whether loss of
H2Bub1 is a general effect occurring during tumor progression
and whether H2Bub1 may exhibit utility as either a diagnostic or
prognostic tumor marker.
What is the function of H2Bub1 during normal physiological
processes? While decreased differentiation correlates with lower
1598 S.A. Johnsen / FEBS Letters 586 (2012) 1592–1601levels of H2Bub1 and higher expression of USP22, it is currently
unclear whether H2Bub1 plays a causative role in controlling cel-
lular differentiation status. Studies in normal cellular differentia-
tion systems will be necessary to address this.
Do H2Bub1 and its upstream regulatory components have tu-
mor and stage-dependent functions? As mentioned above,
H2Bub1 may potentially function primarily by suppressing meta-
static and stem cell-like phenotypes. In this case, the role of
H2Bub1 in solid and hematological malignancies may be com-
pletely different.
Is H2Bub1 a viable therapeutic target? Given the function of
H2Bub1 in diverse nuclear processes including transcription and
DNA repair, this pathway may ultimately be exploited for cancer
treatment. However, additional in vitro, in vivo Xenograft, and
transgenic mouse studies will help determine whether this is a via-
ble option and what tumor types and combination therapies will
be most effective.
Together, addressing these questions will provide a signiﬁcant
advance both in our understanding of H2Bub1 biology as well as
the potential of epigenetic-based therapies for cancer.
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